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a b s t r a c t
A series of oligochitosans (short chain chitosans) prepared by acidic hydrolysis of chitosan and charac-
terized by their molecular weight, polydispersity and degree of deacetylation were used to determine
their anticandidal activities. This study has demonstrated that oligochitosans show a high fungistatic
activity (MIC 8e512 mg/ml) against Candida species and clinical isolates of Candida albicans, which are
resistant to a series of classic antibiotics. Flow cytometry analysis showed that oligochitosan possessed a
high fungicidal activity as well. For the ﬁrst time it was shown that even sub-MIC oligochitosan con-
centration suppressed the formation of C. albicans hyphal structures, cause severe cell wall alterations,
and altered internal cell structure. These results indicate that oligochitosan should be considered as a
possible alternative/additive to known anti-yeast agents in pharmaceutical compositions.
 2014 Elsevier Masson SAS. All rights reserved.
1. Introduction
The ascomycete yeast Candida is the most common cause of
opportunistic mycosis worldwide.
Among Candida species, Candida albicans, Candida tropicalis,
Candida parapsilosis, Candida glabrata, Candida kruisei, Candida
scotti, and Candida guilliermondii are the most widespread ones.
Candida species can be found in the oral cavity, throat, gastroin-
testinal tract, vagina, nails, and skin, and they are responsible for
most (>91%) yeast infections with C. albicans being their major
cause [1]. Over the last decades, the predominant pathogenic
Candida species have changed, and infections caused by non-
albicans Candida species have grown increasingly [2,3].
Conversely, the prominence of non-albicans, such as C. kruisei,
C. parapsilosis and C. tropicalis, has increased their antibiotic resis-
tance bringing challenges for effective antifungal therapy [4,5].
Moreover, misuse of antibiotics and the growing number of
diseases caused by fungi not susceptible to antibiotics have
increased problems with human allergy and have become a big
problem globally [6], especially taking into account that there are a
limited number of antifungal drugs [3]. Therefore, there is a need
for new non-toxic fungicides which would be active against inva-
sive and noninvasive human pathogens and could, at least, reduce
the level of administration and side effects of classic antibiotics [7].
Chitin, poly[b-(1 / 4)-2-acetamido-2-deoxy-D-glucose], is the
most abundant among the natural amino polysaccharides and
represents a constituent of the cell walls of most fungi, algae, in-
sects and crustaceans. Term “chitosan” belongs to a group of
polysaccharides consisting of glucosamine and N-acetylglucos-
amine or glucosamine only, which are derived from chitin and are
soluble in an acidic aqueous media. Conditionally, chitosans can be
distinguished by their molecular weight (MW): high molecular
weight chitosan (HMW), low molecular weight (LMW) chitosan,
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